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Abstract
Background: Based on clinical, histopathological and serological similarities to human celiac disease (CD), we recently
established the rhesus macaque model of gluten sensitivity. In this study, we further characterized this condition based on
presence of anti-tissue transglutaminase 2 (TG2) antibodies, increased intestinal permeability and transepithelial transport
of a proteolytically resistant, immunotoxic, 33-residue peptide from a2-gliadin in the distal duodenum of gluten-sensitive
macaques.
Methodology/Principal Findings: Six rhesus macaques were selected for study from a pool of 500, including two healthy
controls and four gluten-sensitive animals with elevated anti-gliadin or anti-TG2 antibodies as well as history of non-
infectious chronic diarrhea. Pediatric endoscope-guided pinch biopsies were collected from each animal’s distal duodenum
following administration of a gluten-containing diet (GD) and again after remission by gluten-free diet (GFD). Control
biopsies always showed normal villous architecture, whereas gluten-sensitive animals on GD exhibited histopathology
ranging from mild lymphocytic infiltration to villous atrophy, typical of human CD. Immunofluorescent microscopic analysis
of biopsies revealed IgG+ and IgA+ plasma-like cells producing antibodies that colocalized with TG2 in gluten-sensitive
macaques only. Following instillation in vivo, the Cy-3-labeled 33-residue gluten peptide colocalized with the brush border
protein villin in all animals. In a substantially enteropathic macaque with ‘‘leaky’’ duodenum, the peptide penetrated
beneath the epithelium into the lamina propria.
Conclusions/Significance: The rhesus macaque model of gluten sensitivity not only resembles the histopathology of CD
but it also may provide a model for studying intestinal permeability in states of epithelial integrity and disrepair.
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Introduction
CD is an immune disorder induced by dietary gluten from wheat,
rye and barley, and manifests mainly as inflammation, villous
atrophy and crypt hyperplasia in the small intestine [1]. Gastroin-
testinal digestion of gluten releases proteolytically resistant peptide
fragments such as the 33-merLQLQPF (PQPQLPY)3PQPQPF
from a2-gliadin in wheat gluten [2]. These oligopeptides traverse the
intestinal epithelium in individuals with CD by not yet completely
known mechanisms. Deamidation of these peptides is catalyzed by
TG2, a ubiquitous extracellular enzyme in the gut mucosa [3–5]. In
genetically predisposed individuals, deamidated peptides bind with
high affinity to HLA-DQ2 or 8, [6,7] the class II major
histocompatibility complex (MHC) alleles possessed by nearly all
celiac patients [8]. Such DQ2/8-gluten complexes trigger a
deleterious immune response [9,10], which in fully developed
CD results in villous atrophy and crypt hyperplasia of small intestine
[11] as well as nutritional malabsorption and chronic diarrhea
[3].
In parallel to T cell-mediated immune responses to gluten, a
humoral immune response comprising production of AGA and
anti-TG2 antibodies occurs in active CD [12]. Even though villous
atrophy and crypt hyperplasia remain the gold standard for
diagnosis [13], detection of autoantibodies to TG2 is now
considered a highly reliable predictor of CD [14], being 85%
sensitive and 97% specific for disease diagnosis [15]. In celiacs,
subepithelial IgA deposits were detected along the crypt basal
membranes in amounts proportional to dietary gluten intake [16].
In addition, immunofluorescent microscopy revealed subepithelial
IgA and TG2 colocalization [16,17].
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intestinal barrier that facilitates enhanced transepithelial transport
of immunotoxic gluten peptides such as the 33-mer [18]. The
precise cause of such abnormal permeability remains to be
elucidated. For instance, a hormone-like molecule, zonulin, has
been proposed as a trigger [19], being upregulated by gliadin [20]
resulting in downregulation of the tight junction protein zonula
occludens-1 (ZO-1), which physically connects epithelial cells and
prevents leakage through intercellular space [21,22]. Zonulin has
been identified as prehaptoglobin-2 (pre-HP2), a multifunctional
protein [23]. In an alternative hypothesis, increased intestinal
permeability is the result of elevated levels of interferon-c in the
celiac mucosa [24,25].
Animal models are needed to study mechanisms of increased
intestinal permeability and its contribution to transepithelial
passage of gluten peptides, their processing into potent antigens,
and, ultimately, pathogenesis. Ideally, such an animal model
would exhibit those histological and immunological features of CD
most relevant to gluten peptide transport and processing, including
villous atrophy, tight junction disarray and subepithelial accumu-
lation of TG2-specific autoantibodies. We recently reported that
the 33-mer is transported intact across the intestinal epithelium in
enteropathic gluten-sensitive rhesus macaques [26]. In this study,
we show that such animals also feature disease-dependent
subepithelial plasma-like B cells, which stain positive for both
TG2 and immunoglobulin (IgG or IgA). To visualize the
transepithelial uptake of the 33-mer in vivo, we instilled Cy-3-
labeled 33-mer in the duodenum of gluten-sensitive and control
macaques and traced it by confocal microscopy. Further, to
examine the integrity of the intestinal tight junction barrier, we
examined the distribution of ZO-1. Finally, the ZO-1 findings
were corroborated by quantitative measurements of plasma
haptoglobin.
Results
Clinical and serological hallmarks of gluten sensitivity in
macaques
Based on serological pre-screening of 500 randomly selected
colony rhesus macaques, four gluten-sensitive (and two control
animals) were enrolled in this study due to presence of high AGA
or anti-TG2 antibodies (Figure 1). The gluten-sensitive animals
also suffered from non-dehydrating chronic diarrhea of a non-
infectious nature. Upon enrollment, all six macaques were placed
on GFD to determine if they responded by improvement of
clinical scores and decrease in AGA or anti-TG2 antibody levels,
as reported recently [27].
Both control macaques A and B remained seronegative for
AGA and/or anti-TG2 antibodies while on GD, confirming that
dietary changes had no clinical or serological effect on them
(Figure 1A, B). Elevated anti-TG2 antibody in macaque C at the
time of enrollment showed a decline (p,0.01) after placed on
Figure 1. Serological and clinical pre-screening of macaques. Plasma antibody responses to gliadin and TG2 (left axis), and clinical scores
(right axis) of negative control (A, B) and gluten-sensitive (C–F) rhesus macaques while on gluten-free diet (GFD) or gluten-containing diet (GD). Cut-
off values for anti-gliadin and anti-TG2 antibodies are 50 and 25 ELISA units, respectively.
doi:10.1371/journal.pone.0010228.g001
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TG2 antibodies continued to fall for two more months followed by
a return to a level comparable to when it was enrolled (Figure 1C).
No abnormalities were observed in its AGA profile, regardless of
diet (Figure 1C). Initially, its clinical score was 1.560.5 (mild
diarrhea), but remained clinically normal through most of the
study. Macaque D was enrolled due to high level of AGA while on
GD (Figure 1D). When administered GFD for two months, AGA
decreased (p,0.001) to baseline (Figure 1D), as did clinical scores.
When placed on GD for three months, AGA increased
(p,0.0001), along with clinical scores (Figure 1D). Anti-TG2
antibodies in this animal were always at baseline levels. In a
subsequent cycle of GD and GFD (data not shown), AGA
increased again (.200 ELISA units) and clinical scores worsened
to 2.0+0.5 on GD, but improved within two weeks on GFD.
Macaque E was enrolled with an elevated AGA level. It became
negative (p,0.0001) for AGA within one month of GFD
(Figure 1E). After being on GD for one month, AGA increased
(p,0.001) to a level comparable to that at the time of study
enrollment (Figure 1E). A GFD treatment for one month sharply
lowered (p,0.01) AGA to a baseline level again, followed by yet
another increase after being placed back on GD (Figure 1E).
Clinical score decreased from 3 (diarrhea) to 1 (normal) after being
placed on GFD for one month, followed by an increase to 2 on
one month of GD (Figure 1E). Macaque F exhibited elevated anti-
TG2 antibodies at enrollment (Figure 1F). However, these
antibodies did not decrease even after three months on GFD
(Figure 1F). Clinical scores corresponded to a mild diarrhea, which
improved on GFD (Figure 1F).
Histopathological findings
Duodenal biopsies from all four gluten-sensitive macaques were
collected at two time points, first while on GD, and second while in
clinical and serological remission on GFD. Such biopsies were also
collected from the two control animals at corresponding time
points. H&E staining of duodenal tissues from gluten-sensitive
animals revealed variable levels of tissue inflammation while on
GD. All four animals showed intraepithelial lymphocytosis and
infiltration of lamina propria with mononuclear cells (not shown).
Typical gluten-sensitive enteropathy characterized by shortened
and/or flattened villi and crypt hyperplasia was observed in two
out of four gluten-sensitive macaques (Animals D & E, Figure 2B).
No changes were seen in controls (Figure 2A).
Double-positive TG2+IgA+ and TG2+IgG+ autoantibody-
secreting cells
Duodenal biopsies were processed for confocal imaging [28].
Single positive TG2+, IgG+ and IgA+ cells were readily detectable
in all six animals. TG2+ cells were localized mostly in endothelium
and lamina propria, and IgG+ and IgA+ cells in lamina propria.
Double positive TG2+IgG+ and TG2+IgA+ cells [visualized in
yellow due to spectral overlap of green (IgG/IgA) and red (TG2)]
were detected as clusters of plasma-like B cells in lamina propria of
two out of four (animals D & E) gluten-sensitive animals
(Figure 2C, D), but not detected in controls.
Transepithelial passage of a2-gliadin-derived 33-mer
peptide
To study the epithelial entry and transport of the 33-mer gluten
peptide, a fluorescent analogue (0.5 g/L Cy-3-labeled 33-mer) was
instilled directly in distal duodenum of two healthy controls
(animals A & B) and two gluten-sensitive macaques (animals D &
E). The latter had significantly elevated plasma AGA levels
(p,0.001). All animals were on GD. Pinch biopsies were collected
at 0, 20 and 40 min after instillation, immunostained and
visualized by confocal microscopy. Cy-3-labeled 33-mer (red)
was detected at 20 min post-instillation in association with a villus
marker (villin, green) in all macaques (Figure 3). Notably, in
gluten-sensitive animal E with pronounced enteropathy, the 33-
mer was detected beneath the brush border membrane, inside
epithelial cells at 40 min post-instillation (Figure 4). Here, the
peptide appeared as red granules inside ‘‘Goblet cell-like cavities’’
(Figure 4). Absence of nuclei in these vacuoles, evidenced by
nuclear (BoPro-1) staining and DIC, suggested that these vacuoles
could represent gaps left after extrusion of damaged/dying cells
from enteropathic gut (Figure 4, Figure S1). Even further
penetration of Cy-3 33-mer beneath epithelial layer into lamina
propria was seen at 40 min post-instillation in this animal
(Figure 4), whereas the peptide was always detected only at the
brush border in both controls (not shown).
Expression and localization of tight junction protein ZO-1
To evaluate the integrity of intestinal tight junctions, Cy-3-
labeled 33-mer was instilled in the duodenum of gluten-sensitive
enteropathic macaques D & E and control animal B while on GD,
and biopsies collected as described above were stained with anti-
ZO-1 antibody (Table 1). In the control duodenum, ZO-1
exhibited typical continuous honeycomb expression characteristic
of intact tight junctions forming a functional epithelial barrier
(Figure 5A, Figure S2). In both of the gluten-sensitive enteropathic
macaques, ZO-1 expression was markedly reduced to a discon-
tinuous pattern along the luminal side of the epithelial layer
(Figure 5B). Importantly, ZO-1 expression was entirely absent
from the Cy-3 33-mer-containing gaps observed in the entero-
pathic macaques, further confirming epithelial barrier loss.
Plasma haptoglobin in gluten-sensitive macaques before
and after administration of GFD
Given the altered expression of ZO-1 in small intestine of
gluten-sensitive enteropathic macaques, plasma levels of hapto-
globin were measured in all six macaques before and after
administration of GFD. Compared to healthy controls, gluten-
sensitive macaques showed significantly higher (p,0.05) levels of
haptoglobin while on GD (Figure 5C). Moreover, the protein level
was higher (p,0.05) in gluten-sensitive macaques during the time
of AGA or anti-TG2 antibody relapse (GD) than in remission
(GFD). The two control macaques showed no change in plasma
haptoglobin upon administration of GFD (Figure 5C).
Discussion
Recently, we described the non-human primate model of gluten
sensitivity that shares clinical, histological and serological charac-
teristics with CD [26,27]. To further investigate the utility of this
model, the present study sought to: (i) expand our cohort of gluten-
sensitive macaques; (ii) characterize the serological and histological
hallmarks of this condition with emphasis on altered intestinal
permeability; (iii) visualize transepithelial transport of the immu-
nogenic 33-mer peptide from a2-gliadin; and (iv) detect production
of TG2-specific autoantibodies in lamina propria.
A total of 500 Indian rhesus macaques were pre-screened for
presence of anti-gliadin and/or anti-TG2 antibodies by ELISA. At
least four animals were found to be gluten-sensitive based on high
levels of the above antibodies and a history of non-infectious
chronic diarrhea. This rate (1:125) is comparable to incidence of
CD in humans, ranging between 1:266 worldwide to 1:133 in
USA [29]. To determine whether there is a similar genetic basis
Gluten Sensitivity in Macaques
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analogs of the human MHC II alleles DQ2/8 known to be present
in nearly all celiac [8]. Although we recently identified a group of
such candidate MAMU II alleles in rhesus monkeys (unpublished
data), further corroborative analyses need to be conducted with
higher numbers of animals. Our preliminary results suggest that
predisposition for gluten sensitivity in macaques might be
associated with a broader array of alleles than it is in case of
CD and may be independent of MAMU II allele in a
subpopulation of animals.
In addition to the four macaques that met our criteria for
inclusion in this study, five macaques had increased AGA or anti-
TG2 antibodies but no clinical histories of chronic diarrhea. Four
of these were asymptomatic, and one presented with extensive skin
rash. Both AGA and skin rash disappeared in this animal upon
administration of GFD. Asymptomatic or silent forms of CD are
common in humans, and we hypothesize that such forms exist also
in non-human primates. The observation of extraintestinal
manifestation of gluten sensitivity in macaques is in accordance
with the highly polymorphic nature of CD [30,31]. Further studies
on this subject are planned.
Three out of four gluten-sensitive animals enrolled (Figure 1C–
E) responded well to GFD, as observed by a decrease in AGA or
anti-TG2 antibodies. Clinical symptoms were mild but in
agreement with serological results (Figure 1). Macaque C had
high level of anti-TG2 antibodies, but not AGA (Figure 1C).
Macaques D and E responded to dietary changes both
serologically and clinically, but during the last phase of GFD
treatment of macaque E, clinical scores were still elevated
(Figure 1E). It is possible that due to intestinal lesions caused by
gluten exposure, macaque E did not recover fully. Macaque F did
not respond to gluten withdrawal, as anti-TG2 antibodies
remained high (Figure 1F). In humans, GFD-unresponsive cases
are referred to as refractory CD [32]. Animal F could represent a
similar case of refractory gluten sensitivity. Refractory CD patients
often develop cryptic intestinal T-cell lymphomas and phenotyp-
Figure 2. Histopathological and immunofluorescent findings in normal and gluten-sensitive macaque duodenum. An H&E-stained
duodenal biopsy from negative control (A) and two gluten-sensitive enteropathic rhesus macaques characterized by shortened, flattened villi and
lymphocytosis of lamina propria (B). Biopsies were taken while animals were on GD. Confocal microscopy of duodenal tissue section from a
representative animal with gluten-sensitive enteropathy revealed presence of single-positive TG2+ (red), IgG+ /IgA+ (green) cells, as well as TG2+IgG+
(C) and TG2+IgA+ (D) double-positive cells. Double-positive cells are seen as yellow clusters of plasma-like cells due to spectral overlap of red and
green (arrows). These cells are suggestive of the source of anti-TG2 antibodies. The TG2 expression was localized mostly in the endothelium while IgG
and IgA were localized mostly in the lamina propria. Expression of nuclear DNA is seen in blue (C). Differential interference contrast (DIC) was used for
the observation of non-labeled tissues (C, D). Magnification: A & B: 5x; C & D: to a bar scale.
doi:10.1371/journal.pone.0010228.g002
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cytology [33]. Future studies should focus on such features in
those gluten-sensitive macaques that do not respond to GFD.
Typical gluten-sensitive enteropathy characterized by villous
atrophy was observed in macaques D & E (Figure 2B) while
variable degrees of lamina propria lymphocytic infiltrations were
seen in the other two gluten-sensitive animals but not in controls.
One of the important hallmarks of CD is the presence of
circulating autoantibodies against TG2 [15]. TG2 is normally
expressed in small intestine, and other isoforms are in skin, brain,
liver, kidney, etc [34]. Anti-TG2 antibodies are produced by
intestinal mucosa and can be readily detected in intestinal
secretions [35,36]. In active CD, anti-TG2 IgA antibodies target
TG2 and form characteristic deposits in small intestinal epithelial
membrane [37]. In gluten-sensitive macaques C-F but not in
healthy controls, such autoantibody-secreting cells were detected
in duodenal lamina propria (Figure 2C, D). Unlike humans,
however, no subepithelial IgA deposition was observed.
A major objective of this study was to visualize the
transepithelial transport of immunotoxic gliadin peptides across
enteropathic (gluten-sensitive) gut. In intestinal lumen, gastroin-
testinal proteases are the first line of defense against potentially
harmful dietary proteins [38]. Clinical studies suggest that an
altered intestinal barrier is a predetermining factor for develop-
ment of CD [18]. Under normal physiological conditions,
intestinal epithelium is largely impermeable to gliadin, but in
CD patients, gliadin crosses the intestinal barrier and activates the
immune system [18]. Several gliadin-specific T-cell epitopes have
been identified and reported to cluster in proline-rich regions of
the protein [39]. Shan and colleagues (2002) identified the 33-mer
(LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF) to be par-
ticularly important in that it is highly resistant to proteolytic
degradation, contains six partially overlapping copies of three
distinct DQ2-restricted T-cell epitopes and is highly stimulatory
towards T lymphocytes [2]. Research that addresses how this
peptide is transported, how it binds to DQ2 and how it is
processed by APCs for presentation to T-cells should facilitate the
general understanding of CD [40]. The 33-mer has been detected
as a digestive product of ingested gluten in rats and macaques
[41,42]. This peptide can cross the intestinal epithelium in gluten-
Figure 3. Immunofluorescent detection of 33-mer in macaque duodenum. Duodenal tissue section of the normal control macaque (A and
B) on GD. Biopsies were collected at 0 min (A) and 20 min (B) post-instillation with Cy-3-labeled 33-mer, showing the 33-mer in the intestinal lumen
and villous layer (B). Panels C and D correspond to gluten-sensitive animal on GD with duodenal biopsies collected at 20 min post-instillation. Panel C
shows overlap between the 33-mer and villin markers. Panel D shows incursion of 33-mer into the epithelium plus an area where TG2 left the lamina
propria and appeared in epithelium (arrow). In all panels, villin is in green, Cy-3 33-mer in red, and TG2 is in blue. Panels A and C have also nuclear
DNA in gray. DIC was used for the observation of non-labeled tissues. Magnification is to a bar scale.
doi:10.1371/journal.pone.0010228.g003
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Notwithstanding, it is yet unclear how gluten peptides are
transported intact across mucosal epithelium.
In this study, we visualized transepithelial transport of
fluorescently labeled 33-mer directly in duodenum of gluten-
sensitive (D & E) macaques. Inspired by the pioneering work of
Friis et al., [43] the 33-mer was instilled in distal duodenum, and
pinch biopsies taken from the same area up to 40 min post-
instillation. While the 33-mer was seen at intestinal epithelium
brush border of control and gluten-sensitive macaques (Figure 3B-
D), its further penetration beneath epithelium and into lamina
propria was seen only in the latter (Figure 4). A recent study
involving biopsies derived from celiacs revealed similar pattern
[24]. In our study, at 20 and 40 min post-instillation, the 33-mer
was detected in close proximity to TG2 in gluten-sensitive
enteropathic macaque E, although the two labels did not co-
Figure 4. Transepithelial detection of Cy-3-labeled 33-mer in gluten-sensitive enteropathic macaque gut. Duodenal tissue section
obtained from the gluten-sensitive enteropathic macaque at 40 min post-instillation with Cy-3-labeled 33-mer. The 33-mer is seen not only inside the
epithelium (Goblet cell-like cavities) but also beneath the epithelial layer inside the lamina propria, in close proximity of TG2. Villin is labeled in green,
Cy-3 33-mer in red, TG2 in blue, and nuclear DNA in gray. Magnification is to a bar scale.
doi:10.1371/journal.pone.0010228.g004
Table 1. Antibodies used for immunofluorescent staining of rhesus macaque tissues.
Antibody Isotype Working dilution Manufacturer Code
Anti-human IgA-FITC * Goat IgAa 1:100 Sigma-Aldrich F-5259
Anti-monkey IgG-FITC Goat IgGc 1:500 RDI-Fitzgerald RDI-617102012
Anti-human TG2 Mouse IgG1 1:100 ThermoScientific MS-300-P1ABX
Anti-human villin Rabbit IgG 1:3 Cell Signaling Technology 2369
Anti-human ZO-1 Mouse IgG1 1:15 Zymed 33-9100
ToPro-3 (Nuclear DNA) - ** 1:1,000 Invitrogen T-3605
BoPro-1 (Nuclear DNA) - ** 1:2,000 Invitrogen B-3583
*Fluorescein isothiocyanate,
**Dye.
doi:10.1371/journal.pone.0010228.t001
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Further, Cy-3 33-mer was demonstrated inside ‘‘Goblet cell-like
cavities’’ in the enteropathic animal. As these cavities lacked
nuclear staining, we hypothesize that they were associated with
extrusion of epithelial cells (Figure 4, Figure S1). Neither control
animal showed such phenomena.
To investigate the molecular basis for elevated transepithelial
uptake of 33-mer, enteropathic (D & E) and control (B) macaque
duodenal biopsies were stained for tight junctions. The
cytoplasmic protein ZO-1 plays a critical role in maintaining
tight junction integrity by anchoring occludin to the cytoskeleton
via F-actin. In celiacs, ZO-1 expression is downregulated and F-
actin is redistributed [21,22], causing increased intestinal
paracellular permeability [21]. The expression and distribution
of ZO-1 was evaluated in enteropathic and control macaques on
GD. Reduced expression and a discontinuous pattern of ZO-1
was observed at epithelial cell borders in enteropathic macaques,
in stark contrast to the control animals, which exhibited a
continuous, honeycomb pattern with apical localization of ZO-1
(Figure 5A, B, Figure S2). These findings were corroborated by
measurements of plasma haptoglobin. Haptoglobin is associated
with several inflammatory and autoimmune diseases including
CD [44]. There are three major isoforms (Hp1-1, Hp2-1 and
Hp2-2) in humans, predominant in CD patients being Hp2-1,
although a higher prevalence of Hp1-1 was found in patients with
dermatitis herpetiformis [44]. It is still an open question which
isoform/s reflects increased haptoglobin levels measured in
gluten-sensitive macaques in this study. It was suggested that in
non-human primates, haptoglobin resembles human Hp1-1 [45].
Given the elevated plasma haptoglobin in diseased gluten-
Figure 5. Expression of tight junction proteins in normal and gluten-sensitive macaques. Duodenal tissue sections obtained from normal
control (A) and gluten-sensitive enteropathic (B) macaque at 20 min post-instillation with Cy-3-labeled 33-mer. While tight junctions exhibit typical
honeycomb staining pattern in control animal, disrupted and weakened pattern is seen in enteropathic animal. Absence of tight junction staining is
also seen inside the epithelial gaps (B). Cy-3 33-mer (red) is seen in the epithelial layer. Tight junctions appear green. DIC was used for the observation
of non-labeled tissues. Magnification is to a bar scale. Plasma haptoglobin (C) levels in gluten-sensitive and control macaques while on GFD or GD.
The averages 6 SD reflect the group values as measured by ELISA. Significant (p,0.05) decreases in comparison with gluten-sensitive macaques on
GD are indicated by *. Negative sample cut-off =1.05 OD units.
doi:10.1371/journal.pone.0010228.g005
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condition in primates.
Taken together, our results suggest that intestinal barrier
function is compromised in gluten-sensitive enteropathic ma-
caques, similar to celiacs. It is not yet clear how the 33-mer crosses
epithelial barrier in small intestine or whether the epithelium plays
a role in processing the peptide. Loss of intestinal barrier function
and disruption of intercellular tight junctions seem to be pivotal
factors facilitating the pathogenesis of CD, and research directed
at restoring intestinal barrier function may yield novel treatments.
Thus, future studies on intestinal permeability and its modulation
using the rhesus macaque model of gluten sensitivity could provide
insights toward formulation of such therapies.
Materials and Methods
Ethics statement
Approval for all veterinary procedures in this study had been
obtained from the Institutional Animal Care and Use Commit-
tee (Protocol # 3508), Animal Welfare Assurance A-4499-01.
A n i m a l si nt h i sp r o j e c tw e r eu n d e r the full care of veterinarians
o ft h eT u l a n eN a t i o n a lP r i m a t eResearch Center in accordance
with the standards incorporated in the Guide to the Care and
Use of Laboratory Animals (NIH) 78–23 (Revised, 1996). All
veterinary procedures were performed only with sedated
animals.
Serological pre-screening of rhesus macaques for gluten
sensitivity
A total of 500 rhesus macaques (Macaca mulatta) of Indian origin,
simian retrovirus-free and selected randomly with respect to age
and sex, were pre-screened for gluten sensitivity during semi-
annual TNPRC colony inventories by testing for AGA and anti-
TG2 antibodies by indirect ELISA as previously described [27].
Briefly, a peripheral blood sample (3 ml) was obtained from a
femoral vein of each animal while sedated and corresponding
plasma was analyzed. The negative cut-off values were determined
based on subset of twenty normal healthy animals. The average
optical density units +3x SEM were converted to ELISA units.
The cut-offs corresponded to #50 units for AGA and #25 units
for anti-TG2 antibody ELISA. Based on the presence of AGA or
anti-TG2 antibodies at levels significantly (p,0.001) higher than
the negative cut-off, at least four animals out of 500 were
determined to be gluten-sensitive. Of these four, two had high
AGA and two high anti-TG2 antibodies. All four also had a
history of chronic diarrhea of non-infectious nature. Thus, these
four gluten-sensitive and two healthy control macaques were
enrolled into the study.
Diets
Two types of diets were used: A) Gluten-containing diet (GD), a
commercially available chow routinely used to feed the captive
non-human primates (5K63; PMI Nutrition Intl., LLC), contain-
ing 20% (by weight) of crude protein including oats and ground
wheat; and B) Gluten-free diet (GFD), containing all nutrients at
levels identical with GD, except proteins being replaced by gluten-
free sources (5A7Q; PMI Nutrition Intl., LLC).
Clinical evaluation
Clinical scores were recorded daily for all six animals. A blinded
clinical scoring (1–6 scale) was followed as described previously
[27]. Briefly, average weekly scores were calculated as mean 6
standard deviation – based on 7 daily scores.
Peripheral blood, small intestinal biopsy collection, and
diet regimens
Three ml of peripheral (EDTA) blood was collected from a
femoral vein of each of the six macaques at the time of study
assignment and in bi-weekly intervals thereafter. Plasma was
obtained for subsequent testing by ELISA [27]. Pediatric
endoscope-guided pinch (pin-head-sized) biopsies (,10 pieces/
site) were collected from distal duodenum of all animals during
study assignment. The gluten-sensitive animals were then placed
on GFD until AGA or anti-TG2 antibody levels normalized
(Figure 1), at which point pinch biopsies were collected again. The
two control animals were placed on GFD for a month, after which
biopsies were collected again. After collecting the second set of
biopsies, gluten-sensitive animals were placed on GD until
antibodies increased again. Control animals were placed arbi-
trarily on GD for one month before undergoing biopsy (Figure 1).
Biopsies were fixed in Z-fix (Anatech Ltd., Battle Creek, MI) or
2% paraformaldehyde (USB Corp., Cleveland, OH) in PBS
(Gibco-Invitrogen, Carlsbad, CA) for histopathological evaluation
and immunofluorescent studies, respectively [28].
Intraduodenal instillation of a2-gliadin-derived, Cy-3-
labeled 33-mer
To visualize the a2-gliadin 33-mer absorption in an entero-
pathic gut and further study intestinal permeability in gluten-
sensitive macaques, Cy-3-labeled 33-mer (500 mL of 0.5 g/L) was
instilled directly into the distal duodenum of two fully sedated
gluten-sensitive enteropathic and two control animals, while on
GD. Endoscope-guided pinch biopsies (,5 pieces/site) were
collected from the same area at 0, 20 and 40 min post-instillation
and fixed in 2% paraformaldehyde for subsequent immunofluo-
rescent staining [28].
Histopathological examination
Two to three pinch biopsies were fixed in Z-fix and sectioned at
5 mm. Tissue sections were stained with hematoxylin and eosin
(H&E), and inspected under light microscope at 5, 10 and 206
magnification in order to detect histopathology typical of CD.
Immunofluorescent staining and confocal imaging
Two to three pinch biopsies from distal duodenum of each of
the four gluten-sensitive and two control macaques were processed
[28] for confocal imaging. They were fixed in 2% paraformalde-
hyde, cryopreserved in 30% sucrose (Sigma, St. Louis, MO) in
PBS, and snap-frozen in 2562065 mm cryomolds (Sakura
Finetek, Inc., Torrance, CA) containing an optimal-cutting-
temperature compound (Sakura Finetek). The frozen tissue blocks
were cryosectioned (5 mm thick) with a microtome cryostat
(Cryostar HM 560 MV; Microm International GmbH, Waldorf,
Germany) and subjected to immunofluorescence staining. Briefly,
frozen sections were thawed at room temperature for 15 min and
permeabilized with PBS containing 0.2% fish skin gelatin (FSG;
Sigma) and 0.1% Triton X-100 (Sigma) for 20 min at room
temperature. Sections were then washed with PBS-FSG, and
blocked with 10% normal goat serum or normal donkey serum
(NGS or NDS; Gibco-Invitrogen) in PBS containing 0.2% FSG for
1 hour at room temperature in a humidified slide chamber. Tissue
sections were stained with one or combinations of primary
antibodies (Table 1) specific for rhesus IgG, IgA and TG2 in order
to identify anti-TG2 autoantibodies (IgG or IgA).
For visualizing a2-gliadin 33-mer absorption, pinch biopsies
collected at 0, 20 and 40 min post-instillation with Cy-3-labeled
33-mer were processed as above, and tissue sections stained for
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villin and TG2, as well as BoPro-1 nuclear DNA stain. To evaluate
the intestinal epithelium integrity, expression of a tight junction
protein (ZO-1) was examined in the same biopsies by staining with
anti-ZO-1 antibodies (Table 1). Each primary antibody staining
was followed by secondary isotype-specific antibodies tagged with
Alexa Fluor fluorochrome 488 (green), 568 (red) or 633 (blue)
(Molecular Probes-Invitrogen) at 1:1,000 dilution. All antibodies
were diluted in 10% NGS or NDS. Sections were washed with
PBS–FSG–TX-100 for 5 min, followed by a rinse with PBS-FSG
before adding primary or secondary antibodies. Stained tissue
sections were mounted with anti-quenching solution (Sigma).
Imaging was performed with a TCS SP2 True confocal laser
scanning microscope (Leica, Wetzlar, Germany) equipped with
three lasers: an argon-krypton laser at 488 nm (green), a krypton
laser at 568 nm (red), and a helium-neon laser at 633 nm (blue),
that span from the visible to the far-red side of the spectrum.
Differential interference contrast (DIC) imaging for observation of
non-labeled tissue was also used. All samples were read in a
blinded fashion.
Plasma haptoglobin levels
Plasma haptoglobin levels corresponding to time points of
elevated AGA or anti-TG2 antibodies in gluten-sensitive ma-
caques while on GD were compared with those collected while on
GFD using indirect ELISA as described earlier [27]. Briefly,
20 mg/ml plasma protein was used for coating, followed by
chicken anti-human haptoglobin (Abcam, Cambridge, MA)
antibody at 0.4 mg/ml and biotinylated goat anti-chicken (Aves
Labs, Inc., Tigard, OR) antibody (1:500,000) [27]. Plasma from
corresponding time points of both control animals were also
included. The negative cut-off value, determined as earlier,
corresponded to 1.05 optical density units as measured at 492 nm.
Statistical evaluation
Statistical differences of serological and clinical values between
time points corresponding to GD and GFD for each animal were
evaluated using Student’s t-test. P values lower than 0.05 were
considered statistically significant. Prior to enrollment of gluten-
sensitive macaques, animals with AGA or anti-TG2 antibodies at
levels significantly (p,0.001) higher than the negative cut-off value
were selected out of 500 pre-screened macaques.
Supporting Information
Figure S1 Immunofluorescent detection of 33-mer in Goblet
cell-like cavities in gluten-sensitive macaque gut epithelium.
Duodenal tissue section obtained from gluten-sensitive animal
while on GD. Biopsies were collected at 20 min post-instillation
with Cy-3-labeled 33-mer. Confocal microscopy of immunofluor-
escently labeled tissue sections reveals presence of 33-mer inside
the epithelium (arrows). Differential interference contrast (DIC)
suggests the absence of nuclei from the Goblet cell-like cavities (A).
Further corroboration of such finding was performed with nuclear
staining of another tissue section from the same animal (B). Villin
is labeled in green, Cy-3 33-mer in red, TG2 in blue, and nuclear
DNA in gray (C). DIC was used for the observation of non-labeled
tissues. Magnification is to a bar scale.
Found at: doi:10.1371/journal.pone.0010228.s001 (0.44 MB TIF)
Figure S2 Typical tight junction morphology in normal
macaque duodenum. Duodenal tissue sections obtained from
normal control macaque at 20 min post-instillation with Cy-3-
labeled 33-mer. Tight junctions exhibit typical honeycomb
staining pattern in this animal. Tight junctions appear in green,
villin is blue and Cy-3 33-mer (red) is not detected in the epithelial
layer. Magnification is to a bar scale.
Found at: doi:10.1371/journal.pone.0010228.s002 (0.68 MB TIF)
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